NASDAQ:MLYS Mineralys Therapeutics (MLYS) Stock Price, News & Analysis $15.46 +1.00 (+6.88%) As of 03:14 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Mineralys Therapeutics Stock (NASDAQ:MLYS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Mineralys Therapeutics alerts:Sign Up Key Stats Today's Range$14.26▼$15.5250-Day Range$12.87▼$15.5552-Week Range$8.24▼$18.38Volume628,047 shsAverage Volume879,543 shsMarket Capitalization$1.03 billionP/E RatioN/ADividend YieldN/APrice Target$32.25Consensus RatingModerate Buy Company Overview Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania. Read More Mineralys Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks64th Percentile Overall ScoreMLYS MarketRank™: Mineralys Therapeutics scored higher than 64% of companies evaluated by MarketBeat, and ranked 367th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingMineralys Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageMineralys Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Mineralys Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Mineralys Therapeutics are expected to decrease in the coming year, from ($4.23) to ($4.48) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mineralys Therapeutics is -4.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mineralys Therapeutics is -4.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMineralys Therapeutics has a P/B Ratio of 3.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted17.19% of the float of Mineralys Therapeutics has been sold short.Short Interest Ratio / Days to CoverMineralys Therapeutics has a short interest ratio ("days to cover") of 8.8.Change versus previous monthShort interest in Mineralys Therapeutics has recently decreased by 11.05%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMineralys Therapeutics does not currently pay a dividend.Dividend GrowthMineralys Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted17.19% of the float of Mineralys Therapeutics has been sold short.Short Interest Ratio / Days to CoverMineralys Therapeutics has a short interest ratio ("days to cover") of 8.8.Change versus previous monthShort interest in Mineralys Therapeutics has recently decreased by 11.05%, indicating that investor sentiment is improving significantly. News and Social Media3.3 / 5News Sentiment0.98 News SentimentMineralys Therapeutics has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 21 news articles for Mineralys Therapeutics this week, compared to 5 articles on an average week.Search InterestOnly 1 people have searched for MLYS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows3 people have added Mineralys Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Mineralys Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,776,262.00 in company stock.Percentage Held by Insiders33.24% of the stock of Mineralys Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions84.46% of the stock of Mineralys Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Mineralys Therapeutics' insider trading history. Receive MLYS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mineralys Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address MLYS Stock News HeadlinesMineralys Therapeutics, Inc. (NASDAQ:MLYS) Insider David Malcom Rodman Sells 11,365 SharesAugust 15, 2025 | insidertrades.comAdam Scott Levy Sells 807 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) StockJuly 31, 2025 | insidertrades.comHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and declared a historic event would send the yellow metal to $3,150. People laughed at him at the time, but he was off by just two days. Now, Sean has a shocking new prediction for gold … and reveals a little-known way to get ahead of this bull market.August 20 at 2:00 AM | Weiss Ratings (Ad)HC Wainwright Has Positive Forecast for MLYS Q3 EarningsAugust 17 at 2:21 AM | americanbankingnews.comMineralys Therapeutics Advances Hypertension Drug Toward FDA Filing After Strong Clinical ResultsAugust 16, 2025 | msn.comQ3 EPS Forecast for Mineralys Therapeutics Raised by AnalystAugust 16, 2025 | americanbankingnews.comMineralys Therapeutics, Inc. (MLYS) Q2 2025 Earnings Call TranscriptAugust 13, 2025 | seekingalpha.comMineralys Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 12, 2025 | globenewswire.comSee More Headlines MLYS Stock Analysis - Frequently Asked Questions How have MLYS shares performed this year? Mineralys Therapeutics' stock was trading at $12.31 at the start of the year. Since then, MLYS stock has increased by 24.5% and is now trading at $15.32. How were Mineralys Therapeutics' earnings last quarter? Mineralys Therapeutics, Inc. (NASDAQ:MLYS) released its earnings results on Tuesday, August, 12th. The company reported ($0.66) EPS for the quarter, beating analysts' consensus estimates of ($0.78) by $0.12. Read the conference call transcript. When did Mineralys Therapeutics IPO? Mineralys Therapeutics (MLYS) raised $180 million in an initial public offering on Friday, February 10th 2023. The company issued 12,000,000 shares at $14.00-$16.00 per share. Who are Mineralys Therapeutics' major shareholders? Mineralys Therapeutics' top institutional shareholders include Franklin Resources Inc. (2.77%), Jennison Associates LLC (1.90%), Geode Capital Management LLC (1.46%) and American Century Companies Inc. (1.28%). Insiders that own company stock include Brian Taylor Slingsby, Samsara Biocapital Gp, Llc, Ra Capital Management, LP, Hbm Healthcare Investments (Ca, Jon Congleton, Adam Scott Levy and David Malcom Rodman. View institutional ownership trends. How do I buy shares of Mineralys Therapeutics? Shares of MLYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Mineralys Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Mineralys Therapeutics investors own include Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Meta Platforms (META), NVIDIA (NVDA), Netflix (NFLX) and Alphabet (GOOG). Company Calendar Last Earnings8/12/2025Today8/20/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MLYS CIK1933414 Webwww.mineralystx.com Phone888-378-6240FaxN/AEmployees28Year FoundedN/APrice Target and Rating Average Price Target for Mineralys Therapeutics$32.25 High Price Target$48.00 Low Price Target$15.00 Potential Upside/Downside+122.9%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($3.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$177.81 million Net MarginsN/A Pretax MarginN/A Return on Equity-70.44% Return on Assets-65.51% Debt Debt-to-Equity RatioN/A Current Ratio15.12 Quick Ratio15.12 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.73 per share Price / Book3.06Miscellaneous Outstanding Shares66,290,000Free Float44,259,000Market Cap$959.22 million OptionableOptionable Beta-0.29 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:MLYS) was last updated on 8/20/2025 by MarketBeat.com Staff From Our PartnersWashington Thinks They Own Your Bank AccountWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredSilver’s Still Under $35… For Now.Silver is trading around $33—but insiders are betting on a $70 breakout by year’s end. With supply shrinkin...GoldenCrest Metals | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredSmall Washington, DC Group Could Crash US StocksNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mineralys Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mineralys Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.